# Fluvoxamine to Augment Olfactory Recovery For Long COVID-19 Parosmia

> **NCT05216614** · PHASE2 · WITHDRAWN · sponsor: **Washington University School of Medicine**

## Conditions studied

- COVID-19
- Olfactory Disorder
- Parosmia

## Interventions

- **DRUG:** Fluvoxamine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05216614
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-12-14
- **Primary completion:** 2022-02-22
- **Final completion:** 2022-02-22
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Unable to obtain investigational product
- **Last updated:** 2022-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05216614

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05216614, "Fluvoxamine to Augment Olfactory Recovery For Long COVID-19 Parosmia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05216614. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*